| HOME >> BIOLOGY >> TECHNOLOGY |
WASHINGTON, Oct. 20 /PRNewswire/ -- The Repair Stem Cell Institute (RSCI) today announced two additions to its world-leading Science Advisory Board (SAB), extending its stem cell research proficiency in the process. Don Margolis, RSCI chairman, noted that "Our first five appointees had two things in common: pioneering stem cell research and successfully helping patients with a variety of illnesses considered incurable. Today we add two Massachusetts researchers, David Matzilevich, M.D., Ph.D. and Mariano Ubeda, M.D., Ph.D. thus stretching our expertise to fields not being covered by others. They fit well with our innovative five."
According to Margolis, the two new additions cover still more ground. "Dr. Matzilevich's focus is on adult stem cell and cord blood uses as well as molecular-based approaches to Schizophrenia and Bipolar Disorder, and he is contributing greatly to these fields. Dr. Ubeda has made significant scientific contributions to the field of chronic degenerative diseases, and is working on advanced stem cell therapies to try to combat the greatest pandemic in world medical history--Diabetes--a disease for which current stem cell research doesn't begin to match the need. We at RSCI are committed to improving the lives of diabetic patients.
"Our SAB Chairman, Kit Arom, M.D., Ph.D. of Minneapolis and Bangkok, is the first doctor in the world to personally inject stem cells into the heart muscles of over 100 late-stage heart patients, accepting patients with no other options by standard cardiology and improving their lives at a 70% success rate. Now he wants to get involved in the fight against the diabetes pandemic.
"Deputy Chairman Roberto Fernandez Vina, M.D. of Argentina is a world-pioneer, having completed successful clinical trials on heart patients in South America before the first such trial even started in the USA. He is also the author of the first stem cell clinical trial for type 2 Diabetes.
"Zannos Grekos,
'/>"/>
| SOURCE The Repair Stem Cell Institute LLC Copyright©2008 PR Newswire. All rights reserved |